Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (...
Main Authors: | Bettina Gerner, Oliver Scherf-Clavel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/6/778 |
Similar Items
-
A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies
by: Nina Hanke, et al.
Published: (2020-06-01) -
Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021-02-01) -
Cabozantinib and apixaban: an hitherto unreported interaction
by: Daniele Santini, et al.
Published: (2019-09-01) -
Prediction of Severity of Drug-Drug Interactions Caused by Enzyme Inhibition and Activation
by: Alexander Dmitriev, et al.
Published: (2019-10-01) -
Computational modeling of cytochrome P450-mediated drug metabolism
by: Dapkūnas, Justas
Published: (2011)